SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Biocon’s arm acquires R&D capital assets from Pfizer Healthcare India

24 Sep 2019 Evaluate

Biocon’s subsidiary -- Biocon Biologics has acquired R&D capital assets for 60,000 sq. ft. state-of-the-art ‘bench to pilot scale’ Biologics research facility at TICEL Bio Park in Chennai, India. Biocon Biologics has acquired these assets from Pfizer Healthcare India.

The new facility provides Biocon Biologics a significant time advantage in comparison to setting up a Greenfield R&D project and will accelerate the global development of its biosimilars portfolio.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

383.00 2.25 (0.59%)
07-May-2026 15:03 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1837.00
Dr. Reddys Lab 1309.40
Cipla 1363.00
Zydus Lifesciences 939.40
Lupin 2457.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×